Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986769 | 0.63 | HTT (0.49) | MAPTMEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL11852029 | 0.61 | HTT (0.63) | MAPTMEN1ALDH1A1TP53CYP1A2 | |
| (Phenylsulfinyl)Benzene SCHEMBL43199 | 0.61 | TDP1 (0.37) | MAPTALDH1A1HPGDTSHRHSD17B10 | |
| (Phenylsulfinyl)Benzene SCHEMBL29572063 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL12336893 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 | |
| (Phenylsulfinyl)Benzene SCHEMBL11455732 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 | |
| (Phenylsulfinyl)Benzene SCHEMBL30226308 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 | |
| (Phenylsulfinyl)Benzene SCHEMBL11889252 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 | |
| (Phenylsulfinyl)Benzene SCHEMBL29381213 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 | |
| (Phenylsulfinyl)Benzene SCHEMBL29227233 | 0.59 | TDP1 (0.35) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | claimed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| WO-2016160880-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | claimed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250381165-A1 | Method of Use for Benzofuran Compounds | TAMPA BAY RESEARCH INSTITUTE, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250352473-A1 | NANOLIPOSOME COMPOSITIONS AND METHODS OF USING THE SAME | US GOV VETERANS AFFAIRS (US) | 2025-11-20 | — | — | US | disclosed |
| US-12383500-B2 | Nanoliposome compositions and methods of using the same | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2016160880-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2380208-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MAPT 832/4885MEN1 1105/4885ALDH1A1 4784/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | MAPT 3316/4885MEN1 4363/4885ALDH1A1 4393/4885 |
| US-20250381165-A1 | Method of Use for Benzofuran Compounds | CD74, TAP1, TAP2 | MAPT 2893/4885MEN1 4485/4885ALDH1A1 3262/4885 |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | MAPT 2576/4885MEN1 2103/4885ALDH1A1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.